

Title:
Migraine, drug use & Treatment

Reference Number: RDF1282
Date of Response: 27/02/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

A. *How many patients have been treated with the following drugs in the past 4 months:*

Erenumab (Aimovig) - any disease

Eptinezumab (Vyepti) - any disease

Fremanezumab (Ajovy) - any disease

Galcanezumab (Emgality) - any disease

Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Please see table below:

Drug	Patients treated – Trust Total
Erenumab (Aimovig) - any disease	9
Eptinezumab (Vyepti) - any disease	0
Fremanezumab (Ajovy) - any disease	117
Galcanezumab (Emgality) - any disease	19
Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY	107

B. *How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:*

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Botulinum Toxin		

Answer: question B

Please see table below:

Please note - we are not able to split the migraines for the second part of the FOI for question 2 into episodic and chronic migraines. To provide you with this information would require the manual extraction and manipulation of information from various sources. To carry out this work would exceed the appropriate cost limit as set out in Section 12 (1) of the Freedom of Information Act 2000 and is therefore exempt.

Under the Freedom of Information Act 2000 Section 12 (1) and defined in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004, a public authority is not obliged to comply with a request for information if it estimates that the cost of complying would exceed the appropriate limit. The limit of £450 represents the estimated cost of one person spending two and a half days in determining whether the Trust holds the information, locating, retrieving and extracting that information.

*** we can only identify migraine from the ICD-10 coding G43 – Migraines:

Drug	Patients treated – Trust Total
Erenumab	* <5
Eptinezumab	0
Fremanezumab	98
Galcanezumab	13
Botulinum Toxin	96

* <5 In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

These figures are withheld under Section 40(2) due to low staff numbers. The disclosure of which could risk the identification of those patients and breach Caldicott principles.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients/staff and should not be published.